Icosavax (Icosavax) Net Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Icosavax Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Icosavax's Net Income for the three months ended in Sep. 2023 was $-22.04 Mil. Icosavax's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Icosavax's net margin for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for Icosavax's Net Margin % or its related term are showing as below:

ICVX's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -162.58
* Ranked among companies with meaningful Net Margin % only.

Icosavax Net Margin % Historical Data

The historical data trend for Icosavax's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icosavax Net Margin % Chart

Icosavax Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Net Margin %

Icosavax Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Margin %	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Icosavax's Net Margin %

For the Biotechnology subindustry, Icosavax's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Icosavax's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Icosavax's Net Margin % distribution charts can be found below:

* The bar in red indicates where Icosavax's Net Margin % falls into.

Icosavax Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Icosavax's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-91.758	/	0
	=	%

Icosavax's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin	=	Net Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-22.041	/	0
	=	%

Icosavax (NAS:ICVX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Icosavax Net Margin % Related Terms

Thank you for viewing the detailed overview of Icosavax's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Icosavax (Icosavax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Icosavax Inc (NAS:ICVX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1930 Boren Avenue, Suite 1000, Seattle, WA, USA, 98101

Website

https://www.icosavax.com

Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.

Executives

Adam K. Simpson	director, officer: Chief Executive Officer	C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Niranjan Kanesa-thasan	officer: Chief Medical Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Cassia Cearley	officer: Chief Business Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Thomas Joseph Russo	officer: Chief Financial Officer	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032
Douglas Holtzman	officer: Chief Scientific Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Amin Khan	officer: EVP, Head of Research & Dev.	C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Elizabeth Bekiroglu	officer: See Remarks	1616 EASTLAKE AVENUE E, SUITE 208, SEATTLE WA 98102-3793
Charles E Richardson	officer: See Remarks	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Jim Wassil	director	C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
John W. Shiver	director	C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E. SUITE 208, SEATTLE WA 98102
Anofi	10 percent owner	46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017
Nanodimension Iii, L.p.	10 percent owner	GOVERNORS SQUARE UNIT 3-213, 23 LIME TREE BAY AVE, P.O. BOX 526, WEST BAY, GRAND CAYMAN E9 KY1-1302
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807